Collegium Pharmaceutical is leveraging the upcoming PAINWeek 2025 conference to showcase a significant body of real-world data (RWD) supporting its pain management portfolio, including Belbuca and Xtampza ER. The nine posters slated for presentation signal a strategic emphasis on demonstrating the clinical and economic value of these treatments in a challenging market.
This move raises a crucial question: can robust RWD differentiate Collegium’s opioid offerings in an increasingly scrutinized and competitive landscape? The company clearly aims to position itself as a responsible player in pain management, emphasizing data transparency and evidence-based decision-making for healthcare professionals (HCPs). This strategy is critical given the ongoing opioid crisis and the heightened scrutiny surrounding these medications.
The focus on RWD directly addresses the growing demands from payers and healthcare systems for evidence of real-world effectiveness and cost-effectiveness. Several posters will analyze the economic burden of chronic low back pain patients transitioned to Belbuca or other long-acting opioids, offering valuable insights for managed care decision-makers. Other studies compare Belbuca to oral Schedule II opioids in terms of treatment characteristics, safety profiles, and opioid-use disorder outcomes, providing crucial data for HCPs weighing treatment options.
This commitment to generating and disseminating RWD aligns with broader industry trends. Pharmaceutical companies are increasingly recognizing the strategic importance of RWD in demonstrating product value beyond clinical trials. This is especially critical in therapeutic areas such as pain management, where long-term outcomes and real-world adherence significantly impact treatment success. The insights gleaned from these studies could significantly impact market access and formulary positioning for Collegium’s products.
The data presented at PAINWeek 2025 will be closely scrutinized by competitors, payers, and healthcare professionals alike. The key question remains: will this RWD translate into improved market share and payer acceptance for Collegium’s pain portfolio? The ability to demonstrate tangible, real-world benefits, particularly in terms of safety and cost-effectiveness, will be essential for Collegium’s success in a complex and evolving pain management market.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
